I. Profitability
The profit of Guangdong Kangmei Pharmaceutical Company in the third quarter was meager, which was about 10% lower than the same period of last year. Knowing the capital status, Kangmei Bio (code: 83554 1. NQ) released 202 1 semi-annual report. On June 30th, 20021,1-202 1, the company realized an operating income of 70,820,300 yuan, a year-on-year increase of 2 1.24%, a net profit of 439,200 yuan and a loss of 9,209,700 yuan in the same period last year.
The company's industry is biological products. At the end of the reporting period, the total assets were 388 million yuan, the operating profit was 65.438+0.3472 million yuan, the accounts receivable was 65.438+0.40 billion yuan, the net cash flow from operating activities was 62.65438+0.38 million yuan, and the cash received from selling goods and providing services was 79.7375 million yuan. Kangmei Bio, whose full name is Shenzhen Kangmei Biotechnology Co., Ltd., was established on February 29, 2007, and is now the general manager of Zhang Jingcheng. Its main business is research and development, production and sales of in vitro diagnostic reagents and instruments.
Second, Kangmeiye
Kangmei Pharmaceutical said that during the reporting period, the company focused on its main business and adjusted its business strategy. Due to the epidemic situation and repayment of debt principal and interest, its operating cash flow was affected, resulting in a decline in income. At present, Kangmei Pharmaceutical's business system covers the cultivation and resource integration of authentic Chinese herbal medicines in the upper reaches, the production and sales of Chinese herbal medicines, Chinese herbal pieces and health foods in the middle reaches, and smart pharmacies and chain pharmacies in the lower reaches.
: Kangmei Pharmaceutical Co., Ltd., referred to as "Kangmei Pharmaceutical" (SSE: 6005 18). 1997, founded by private entrepreneur Mr. Ma Xingtian, is located in Puning City, Guangdong Province, formerly known as "Guangdong Kangmei Pharmaceutical Co., Ltd.".
1, Kangmei Pharmaceutical
In 2000, the share reform began. It is one of the large-scale private pharmaceutical enterprises integrating pharmaceutical supply and marketing, Chinese herbal pieces, Chinese herbal medicines and medical devices. The company passed the share-trading reform. Kangmei Pharmaceutical Co., Ltd. (hereinafter referred to as "Kangmei Pharmaceutical") was established on 1997. It is a modern large-scale pharmaceutical enterprise and a national key high-tech enterprise focusing on the production of Chinese herbal pieces, chemical raw materials and preparations, and integrating drug production, research and development, and marketing of drugs and medical devices.
2. Development status
Kangmei Pharmaceutical Co., Ltd. (6005 18) is an enterprise with the largest production scale and the most varieties in Chinese herbal pieces industry. The main products are Comedy Tetra Pak, Comedy Nosa, Comedy Xinping and Comedy Peining. In the first quarter of 2008, the company achieved a year-on-year increase of 43% in sales revenue, a rapid increase of 172% in net profit and an earnings per share of 0.08 yuan. The blueprint for industrial integration has taken shape. 2007 is a year of strategic layout of the company. The company insists on the industrialization of Chinese herbal pieces as the core and gradually extends to the upstream and downstream of the industrial chain. Establish Chinese medicine logistics port and Chinese medicine processing base, control the upstream Chinese medicine resources, and take a step toward the whole country.